← Back to Search

AH-HA EHR Tool for Heart Health in Cancer Survivors (AH-HA Trial)

N/A

Waitlist Available

Led By Kathryn Weaver, MD

Research Sponsored by Wake Forest University Health Sciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age >= 18 years.

Survivors must have no evidence of disease at the time of last medical visit for all cancers, except non-melanoma skin disease.

Must not have

Survivors will be excluded if they have a history of cancer recurrence for any cancer other than non-melanoma skin disease.

Survivor does not speak English or Spanish.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

No Placebo-Only Group

Summary

This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.

Who is the study for?

This trial is for adults over 18 who are cancer survivors (specifically of breast, prostate, colorectal, endometrial cancers or Hodgkin and non-Hodgkin lymphomas) with no current evidence of disease. They must understand English or Spanish, consent verbally to participate, be able to complete a follow-up in one year and have finished curative treatment at least 6 months ago.

What is being tested?

The study tests an electronic health record tool called AH-HA designed to improve heart health discussions between patients and doctors. It will also look at whether the tool helps increase referrals to primary care/cardiology and promotes activities that reduce cardiovascular risk among cancer survivors.

What are the potential side effects?

Since this intervention involves using a digital assessment tool rather than medication or medical procedures, traditional physical side effects are not expected. However, there may be indirect effects on healthcare practices.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I am cancer-free except for non-melanoma skin conditions.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have not had a cancer recurrence except for non-melanoma skin cancer.

Select...

I do not speak English or Spanish.

Select...

I am not on active surveillance for prostate cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Proportion of patients reporting at least one non-ideal or missing CVH topic

Secondary study objectives

CVH behaviors recorded in the past year

CVH factors recorded in the past year

Completed visits with primary care providers and cardiology

+5 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention - AH-HA toolExperimental Treatment1 Intervention

With assistance from the study team, the clinic will implement the AH-HA tool in the clinics' EPIC EHR. Providers at the intervention sites will be trained to use the tool during routine follow-up care with survivors. During a routine follow-up care appointment, the provider will use the AH-HA tool with enrolled patients.

Group II: Usual CareActive Control1 Intervention

Usual care practices will conduct routine follow-up care visits for enrolled survivors following typical clinic practice, without use of the AH-HA tool.

0 / 5Eligibility criteria met